JP2008545718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008545718A5 JP2008545718A5 JP2008513829A JP2008513829A JP2008545718A5 JP 2008545718 A5 JP2008545718 A5 JP 2008545718A5 JP 2008513829 A JP2008513829 A JP 2008513829A JP 2008513829 A JP2008513829 A JP 2008513829A JP 2008545718 A5 JP2008545718 A5 JP 2008545718A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydrogen
- allyl
- halogen
- short chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000002431 hydrogen Chemical group 0.000 claims 8
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical group 0.000 claims 6
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000262 haloalkenyl group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 claims 2
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 claims 2
- 229960005552 PAC-1 Drugs 0.000 claims 2
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- -1 aldehyde compound Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 0 *=C(c1ccccc1C=O)O Chemical compound *=C(c1ccccc1C=O)O 0.000 description 3
- LLVQQQQUKUEOOW-UHFFFAOYSA-N CC(C)c1ccc(C)c(O)c1C=O Chemical compound CC(C)c1ccc(C)c(O)c1C=O LLVQQQQUKUEOOW-UHFFFAOYSA-N 0.000 description 1
- JECYUBVRTQDVAT-UHFFFAOYSA-N CC(c(cccc1)c1O)=O Chemical compound CC(c(cccc1)c1O)=O JECYUBVRTQDVAT-UHFFFAOYSA-N 0.000 description 1
- XFVZSRRZZNLWBW-UHFFFAOYSA-N CCN(CC)c1ccc(C=O)c(O)c1 Chemical compound CCN(CC)c1ccc(C=O)c(O)c1 XFVZSRRZZNLWBW-UHFFFAOYSA-N 0.000 description 1
- OFQBYHLLIJGMNP-UHFFFAOYSA-N CCOc1cccc(C=O)c1O Chemical compound CCOc1cccc(C=O)c1O OFQBYHLLIJGMNP-UHFFFAOYSA-N 0.000 description 1
- TVGIYZVZBKAJRR-UHFFFAOYSA-N NC(Oc1ccccc11)=C(C=O)C1=O Chemical compound NC(Oc1ccccc11)=C(C=O)C1=O TVGIYZVZBKAJRR-UHFFFAOYSA-N 0.000 description 1
- PHQPPUMEXCUXDN-UHFFFAOYSA-N Nc1ccc(C=O)c(O)c1 Chemical compound Nc1ccc(C=O)c(O)c1 PHQPPUMEXCUXDN-UHFFFAOYSA-N 0.000 description 1
- FSMYWBQIMDSGQP-UHFFFAOYSA-N O=CC1=COc2ccccc2C1=O Chemical compound O=CC1=COc2ccccc2C1=O FSMYWBQIMDSGQP-UHFFFAOYSA-N 0.000 description 1
- CKXYCDPQXQTEFZ-UHFFFAOYSA-N O=CC1=Nc2c1cccc2 Chemical compound O=CC1=Nc2c1cccc2 CKXYCDPQXQTEFZ-UHFFFAOYSA-N 0.000 description 1
- GPSUJFRHMYUDNV-UHFFFAOYSA-N OC(CCC1)C1C=O Chemical compound OC(CCC1)C1C=O GPSUJFRHMYUDNV-UHFFFAOYSA-N 0.000 description 1
- XPEUTONKFADCGE-UHFFFAOYSA-N OC(CCCC1)C1C=O Chemical compound OC(CCCC1)C1C=O XPEUTONKFADCGE-UHFFFAOYSA-N 0.000 description 1
- JHZOXYGFQMROFJ-UHFFFAOYSA-N Oc(c(Br)c1)c(C=O)cc1Br Chemical compound Oc(c(Br)c1)c(C=O)cc1Br JHZOXYGFQMROFJ-UHFFFAOYSA-N 0.000 description 1
- YNMHDJBZJBEMSV-UHFFFAOYSA-N Oc(c(C=O)c1)ccc1-[n]1cccc1 Chemical compound Oc(c(C=O)c1)ccc1-[n]1cccc1 YNMHDJBZJBEMSV-UHFFFAOYSA-N 0.000 description 1
- FABVMBDCVAJXMB-UHFFFAOYSA-N Oc(c(Cl)c1)c(C=O)cc1Cl Chemical compound Oc(c(Cl)c1)c(C=O)cc1Cl FABVMBDCVAJXMB-UHFFFAOYSA-N 0.000 description 1
- QPNOPMDDTQEIIG-UHFFFAOYSA-N Oc(cc1)c(C=O)cc1-c(ccc(F)c1)c1F Chemical compound Oc(cc1)c(C=O)cc1-c(ccc(F)c1)c1F QPNOPMDDTQEIIG-UHFFFAOYSA-N 0.000 description 1
- NTCCNERMXRIPTR-UHFFFAOYSA-N Oc1c(C=O)c2ccccc2cc1 Chemical compound Oc1c(C=O)c2ccccc2cc1 NTCCNERMXRIPTR-UHFFFAOYSA-N 0.000 description 1
- DYWIMAXMAVMDOV-QZQOTICOSA-N Oc1cc(/N=N/c(cc2)ccc2S(Nc2ncccc2)(=O)=O)ccc1C=O Chemical compound Oc1cc(/N=N/c(cc2)ccc2S(Nc2ncccc2)(=O)=O)ccc1C=O DYWIMAXMAVMDOV-QZQOTICOSA-N 0.000 description 1
- BTQAJGSMXCDDAJ-UHFFFAOYSA-N Oc1cc(O)c(C=O)c(O)c1 Chemical compound Oc1cc(O)c(C=O)c(O)c1 BTQAJGSMXCDDAJ-UHFFFAOYSA-N 0.000 description 1
- QUUNMPSDKIURJD-UHFFFAOYSA-N Oc1cccc(-c2c3cccc2)c1C3=O Chemical compound Oc1cccc(-c2c3cccc2)c1C3=O QUUNMPSDKIURJD-UHFFFAOYSA-N 0.000 description 1
- IAVREABSGIHHMO-UHFFFAOYSA-N Oc1cccc(C=O)c1 Chemical compound Oc1cccc(C=O)c1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 description 1
- HJIAMFHSAAEUKR-UHFFFAOYSA-N Oc1ccccc1C(c1ccccc1)=O Chemical compound Oc1ccccc1C(c1ccccc1)=O HJIAMFHSAAEUKR-UHFFFAOYSA-N 0.000 description 1
- RFBOLEJBSGUBPZ-UHFFFAOYSA-N Oc1ccccc1CC=O Chemical compound Oc1ccccc1CC=O RFBOLEJBSGUBPZ-UHFFFAOYSA-N 0.000 description 1
- IHFRMUGEILMHNU-UHFFFAOYSA-N [O-][N+](c(cc1C=O)ccc1O)=O Chemical compound [O-][N+](c(cc1C=O)ccc1O)=O IHFRMUGEILMHNU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68480705P | 2005-05-26 | 2005-05-26 | |
| US60/684,807 | 2005-05-26 | ||
| US74387806P | 2006-03-28 | 2006-03-28 | |
| US60/743,878 | 2006-03-28 | ||
| US11/420,425 | 2006-05-25 | ||
| US11/420,425 US20070049602A1 (en) | 2005-05-26 | 2006-05-25 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| PCT/US2006/020910 WO2006128173A2 (en) | 2005-05-26 | 2006-05-26 | Selective apoptotic induction in cancer cells including activation of procaspase-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012251584A Division JP5907852B2 (ja) | 2005-05-26 | 2012-11-15 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008545718A JP2008545718A (ja) | 2008-12-18 |
| JP2008545718A5 true JP2008545718A5 (enExample) | 2009-07-16 |
| JP5513741B2 JP5513741B2 (ja) | 2014-06-04 |
Family
ID=37452994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513829A Active JP5513741B2 (ja) | 2005-05-26 | 2006-05-26 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
| JP2012251584A Active JP5907852B2 (ja) | 2005-05-26 | 2012-11-15 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012251584A Active JP5907852B2 (ja) | 2005-05-26 | 2012-11-15 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070049602A1 (enExample) |
| EP (3) | EP2634581A1 (enExample) |
| JP (2) | JP5513741B2 (enExample) |
| AU (1) | AU2006251978A1 (enExample) |
| CA (1) | CA2610366A1 (enExample) |
| DK (1) | DK1893210T3 (enExample) |
| ES (1) | ES2763156T3 (enExample) |
| IL (1) | IL187603A0 (enExample) |
| MX (1) | MX2007014843A (enExample) |
| WO (1) | WO2006128173A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049602A1 (en) * | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| WO2008134474A2 (en) * | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| WO2010091382A1 (en) | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| WO2010102513A1 (zh) * | 2009-03-11 | 2010-09-16 | 深圳市湘雅生物医药研究院 | 高哌嗪乙酰肼类衍生物及其制备方法和用途 |
| CN101805338B (zh) * | 2010-04-06 | 2014-10-15 | 沈阳药科大学 | 噁二唑基哌嗪衍生物及其用途 |
| US8916705B2 (en) * | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
| EP2819661B1 (en) | 2012-03-02 | 2016-11-09 | The Board of Trustees of the University of Illionis | Potent anticancer activity via dual compound activation |
| MX365392B (es) * | 2012-03-06 | 2019-05-31 | Univ Illinois | Composición de combinación de pac-1 y doxorrubicina. |
| JP6222608B2 (ja) * | 2012-03-06 | 2017-11-01 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 膠芽腫のためのプロカスパーゼ併用療法 |
| US9249116B2 (en) * | 2012-08-03 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
| CN105218399B (zh) | 2014-05-30 | 2018-02-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种取代乙酰肼类衍生物、其制备方法及用途 |
| WO2016197129A1 (en) | 2015-06-05 | 2016-12-08 | The Board Of Trustees Of The University Of Illinois | Pac-1 combination therapy |
| EP3326631B1 (en) * | 2015-07-23 | 2021-07-14 | Zhimin Wang | Compound pac-1 or salt thereof, and pharmaceutical composition comprising same |
| WO2017015784A1 (zh) * | 2015-07-24 | 2017-02-02 | 深圳市湘雅生物医药研究院 | 奥比特嗪-富马酸盐、水合物、晶型及其制备方法 |
| CN105085421B (zh) * | 2015-07-24 | 2017-12-26 | 深圳市湘雅生物医药研究院 | 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法 |
| AU2018368453B2 (en) * | 2017-11-17 | 2024-05-30 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
| KR20210084442A (ko) | 2018-10-05 | 2021-07-07 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 포도막 흑색종 치료를 위한 병용 요법 |
| WO2025129066A1 (en) * | 2023-12-15 | 2025-06-19 | The Regents Of The University Of California | Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4068666B2 (ja) * | 1997-05-22 | 2008-03-26 | ザ バーナム インスティチュート | カスパーゼ活性のアポトーシスインヒビター（ｉａｐ）タンパク質調節を変える薬剤についてのスクリーニングアッセイ |
| US6403765B1 (en) | 1998-06-16 | 2002-06-11 | Thomas Jefferson University | Truncated Apaf-1 and methods of use thereof |
| AU5205499A (en) | 1998-07-27 | 2000-02-21 | Pharmacia & Upjohn Company | Method for autoactivation of procaspase 8 |
| US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| WO2002048329A2 (en) | 2000-11-20 | 2002-06-20 | Idun Pharmaceuticals, Inc. | Membrane derived caspase-3, compositions comprising the same and methods of use therefor |
| WO2002069995A2 (en) * | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| KR100439425B1 (ko) * | 2001-03-22 | 2004-07-05 | (주)바이오케어 | 잔토리졸을 포함하는 조성물 및 그 용도 |
| US6878743B2 (en) | 2001-09-18 | 2005-04-12 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| CA2508690A1 (en) * | 2002-12-10 | 2004-06-24 | Ottawa Health Research Institute | Modulation of stem cell differentiation by modulation of caspase-3 activity |
| WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
| US20070049602A1 (en) * | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
-
2006
- 2006-05-25 US US11/420,425 patent/US20070049602A1/en not_active Abandoned
- 2006-05-26 CA CA002610366A patent/CA2610366A1/en not_active Abandoned
- 2006-05-26 WO PCT/US2006/020910 patent/WO2006128173A2/en not_active Ceased
- 2006-05-26 JP JP2008513829A patent/JP5513741B2/ja active Active
- 2006-05-26 EP EP13166147.2A patent/EP2634581A1/en not_active Withdrawn
- 2006-05-26 MX MX2007014843A patent/MX2007014843A/es not_active Application Discontinuation
- 2006-05-26 DK DK06771588.8T patent/DK1893210T3/da active
- 2006-05-26 ES ES06771588T patent/ES2763156T3/es active Active
- 2006-05-26 EP EP06771588.8A patent/EP1893210B1/en active Active
- 2006-05-26 EP EP13166145.6A patent/EP2659884A3/en not_active Withdrawn
- 2006-05-26 AU AU2006251978A patent/AU2006251978A1/en not_active Abandoned
-
2007
- 2007-11-25 IL IL187603A patent/IL187603A0/en unknown
-
2012
- 2012-11-15 JP JP2012251584A patent/JP5907852B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008545718A5 (enExample) | ||
| TWI385160B (zh) | 用於治療增生性疾病的化合物 | |
| JP2017531041A5 (enExample) | ||
| JP2002543185A5 (enExample) | ||
| JP2004533444A5 (enExample) | ||
| JP2012503621A5 (enExample) | ||
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| WO2005113537B1 (en) | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| JP2005526857A5 (enExample) | ||
| JP2006524660A5 (enExample) | ||
| AU2006272652B2 (en) | 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders | |
| JP2007246474A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| MA27390A1 (fr) | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique | |
| RU2007130802A (ru) | Пуриновые производные в качестве агонистов рецептора а2а | |
| JP2006504738A5 (enExample) | ||
| JP2004529953A5 (enExample) | ||
| JP2010506919A5 (enExample) | ||
| JP2014519507A5 (enExample) | ||
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| JP2010514734A5 (enExample) | ||
| JP2003508523A5 (enExample) | ||
| JP2006518765A5 (enExample) | ||
| RU2007128080A (ru) | Производные пирролидиния в качестве мускариновых рецепторов мз | |
| JP2004517151A5 (enExample) |